病毒学报

参考文献

[1]Adler J L,Zickl R.Winter vomiting disease[J].J Infect Dis,1969,119(6):668-673.

[2]Kapikian A Z,Wyatt R G,Dolin R,Thornhill T S,Kalica A R,Chanock R M.Visualization by immune electron microscopy of a 27-nm particle associated with acute infectious nonbacterial gastroenteritis[J].J Virol,1972,10(5):1075-1081.

[3]VinjéJ,Doern G V.Advances in laboratory methods for detection and typing of norovirus[J].J Clin Microbiol,2015,53(2):373-381.

[4]Singh B K,Leuthold M M,Hansman G S.Structural constraints on human norovirus binding to histo-blood group antigens[J/OL].m Sphere,2016,1(2):e00049-16.

[5]Fang H,Tan M,Xia M,Wang L,Jiang X.Norovirus P particle efficiently elicits innate,humoral and cellular immunity[J/OL].PLo S One,2013,8(4):e63269.

[6]Xia M,Huang P,Sun C,Han L,Vago F S,Li K,Zhong W,Jiang W,Klassen J S,Jiang X,Tan M.Bioengineered norovirus S-60 nanoparticles as a multifunctional vaccine platform[J].Acs Nano,2018,12(11):10665-10682.

[7]Bertolotti-Ciarlet A,White L J,Chen R,Prasad B VV,Estes M K.Structural requirements for the assembly of Norwalk virus-like particles[J].J Virol,2002,76(8):4044-4055.

[8]Bertolotti-Ciarlet A,Crawford S E,Hutson A M,Estes M K.The 3′end of Norwalk virus m RNA contains determinants that regulate the expression and stability of the viral capsid protein VP1:a novel function for the VP2 protein[J].J Virol,2003,77(21):11603-11615.

[9]Vongpunsawad S,Prasad B V V,Estes M K.Norwalk virus minor capsid protein VP2 associates within the VP1 shell domain[J].J Virol,2013,87(9):4818-4825.

[10]Liu Z,Zhang M,Shen Z,Chen H,Zhang W,Xu X,Lai Z,Sun W,Zhao Z,Zhang J.The coordinating role of the human norovirus minor capsid protein VP2 is essential to functional change and nuclear localization of the major capsid protein VP1[J].Arch Virol,2019,164:1173-1180.

[11]Lin Y,Fengling L,Lianzhu W,Yuxiu Z,Yanhua J.Function of VP2 protein in the stability of the secondary structure of virus-like particles of genogroup II norovirus at different p H levels:function of VP2 protein in the stability of No V VLPs[J].J Microbiol,2014,52(11):970-975.

[12]Parrino T A,Schreiber D S,Trier J S,Kapikian A Z,Blacklow N R.Clinical immunity in acute gastroenteritis caused by Norwalk agent[J].N Engl J Med,1977,297(2):86-89.

[13]Tan M,Jiang X.Norovirus-host interaction:Multi-selections by human histo-blood group antigens[J].Trends Microbiol,2011,19(8):382-388.

[14]Mallory M L,Lindesmith L C,Graham R L,Baric RS.GII.4 human norovirus:Surveying the antigenic landscape[J].Viruses-Basel,2019,11(2):177.

[15]Singh B K,Leuthold M M,Hansman G S.Human noroviruses′fondness for histo-blood group antigens[J].J Virol,2015,89(4):2024-2040.

[16]Karangwa C K,Parra G I,Bok K,Johnson J A,Levenson E A,Green K Y.Sequential gastroenteritis outbreaks in a single year caused by norovirus genotypes GII.2 and GII.6 in an institutional setting[J].Open Forum Infect Di,2017,4(4):ofx236.DOI:10.1093/ofid/ofx236.

[17]Kilic T,Koromyslova A,Hansman G S.Structural basis for human norovirus capsid binding to bile acids[J/OL].J Virol,2019,93(2):e01581-01518.

[18]Schroten H,Hanisch F-G,Hansman G S.Human norovirus interactions with histo-blood group antigens and human milk oligosaccharides[J].J Virol,2016,90(13):5855-5859.

[19]Chan M C W,Lee N,Hung T-N,Kwok K,Cheung K,Tin E K Y,Lai R W M,Nelson E A S,Leung TF,Chan P K S.Rapid emergence and predominance of a broadly recognizing and fast-evolving norovirus GII.17variant in late 2014[J].Nat Commun,2015,6:10061.

[20]van Beek J,de Graaf M,Al-Hello H,Allen D J,Ambert-Balay K,Botteldoom N,Brytting M,Buesa J,Cabrerizo M,Chan M,Cloak F,Di Bartolo I,Guix S,Hewitt J,Iritani N,Jin M,Johne R,Lederer I,Mans J,Martella V,Maunula L,Mc Allister G,Niendorf S,Niesters H G,Podkolzin A T,Poljsak-Prijatelj M,Rasmussen L D,Reuter G,Tuite G,Kronerman A,Vennema H,Koopmans M P G,Noro Net.Molecular surveillance of norovirus,2005-16:an epidemiological analysis of data collected from the Noro Net network[J].Lancet Infect Dis,2018,18(5):545-553.

[21]Lindesmith L C,Brewer-Jensen P D,Mallory M L,Debbink K,Swann E W,Vinje J,Baric R S.Antigenic characterization of a novel recombinant GII.P16-GII.4Sydney norovirus strain with minor sequence variation leading to antibody escape[J].J Infect Dis,2018,217(7):1145-1152.

[22]Tohma K,Lepore C J,Ford-Siltz L A,Parra G I.Evolutionary dynamics of non-GII genotype 4(GII.4)noroviruses reveal limited and independent diversification of variants[J].J Gen Virol,2018,99(8):1027-1035.

[23]Qian Y,Song M,Jiang X,Xia M,Meller J,Tan M,Chen Y,Li X,Rao Z.Structural adaptations of Norovirus GII.17/13/21 lineage through two distinct evolutionary paths[J/OL].J Virol,2019,93(1):e01655-18.DOI:10.1128/JVI.01655-18.

[24]Lindesmith L C,Donaldson E F,Baric R S.Norovirus GII.4 Strain antigenic variation[J].J Virol,2011,85(1):231-242.

[25]Lucero Y,Vidal R,O′Ryan G M.Norovirus vaccines under development[J].Vaccine,2018,36(36):5435-5441.

[26]Lo Bue A D,Lindesmith L,Yount B,Harrington P R,Thompson J M,Johnston R E,Moe C L,Baric R S.Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains[J].Vaccine,2006,24(24):5220-5234.

[27]Heinimaki S,Malm M,Vesikari T,Blazevic V.Parenterally administered norovirus GII.4 virus-like particle vaccine formulated with aluminum hydroxide or monophosphoryl lipid A adjuvants induces systemic but not mucosal immune responses in mice[J/OL].JImmuno Res,2018,2018:3487095.DOI:10.1155/2018/3487095.

[28]Springer M J,Ni Y,Finger-Baker I,Ball J P,Hahn J,Di Marco A V,Kobs D,Horne B,Talton J D,Cobb RR.Preclinical dose-ranging studies of a novel dry powder norovirus vaccine formulation[J].Vaccine,2016,34(12):1452-1458.

[29]Han M G,Cheetham S,Azevedo M,Thomas C,Saif L J.Immune responses to bovine norovirus-like particles with various adjuvants and analysis of protection in gnotobiotic calves[J].Vaccine,2006,24(3):317-326.

[30]Kim L,Liebowitz D,Lin K,Kasparek K,Pasetti M F,Garg S J,Gottlieb K,Trager G,Tucker S N.Safety and immunogenicity of an oral tablet norovirus vaccine,a phase I randomized,placebo-controlled trial[J/OL].JCI Insight,2018,3(13):e121077.

[31]Atmar R L,Baehner F,Cramer J P,Lloyd E,Sherwood J,Borkowski A,Mendelman P M,Group NO R S.Antibody persistence to two Virus-Like Particle norovirus vaccine candidate formulations in healthy adults:one-year follow-up with memory probe vaccination[J].J Infect Dis,2019,220(4):603-614.

[32]Jones M K,Grau K R,Costantini V,Kolawole A O,de Graaf M,Freiden P,Graves C L,Koopmans M,Wallet S M,Tibbetts S A,Schultz-Cherry S,Wobus CE,VinjéJ,Karst S M.Human norovirus culture in Bcells[J].Nat Protoc,2015,10(12):1939-1947.

[33]Ettayebi K,Crawford S E,Murakami K,Broughman JR,Karandikar U,Tenge V R,Neill F H,Blutt S E,Zeng X L,Qu L,Kou B,Opekun A R,Burrin D,Graham D Y,Ramani S,Atmar R L,Estes M K.Replication of human noroviruses in stem cell-derived human enteroids[J].Science,2016,353(6306):1387-1393.